Global Briefs: Shionogi, Lilly, Pfizer, Sanofi, Merck & More 

A roundup of news from the large and mid-sized bio/pharmaceutical companies featuring Shionogi, Eli Lilly and Company, Pfizer, AbbVie, Sanofi, Biogen, Vertex Pharmaceuticals, Merck, Novo, BeOne Medicines, and Gilead Sciences. Highlights below.  

For the latest news roundup on small and Emerging Pharma companies, see Biotech Briefs. 

M&A News 
* Shionogi Completes $2-Bn Acquisition of Intra Bio
* Lilly To Acquire Calytrix Bio for $1.5 Bn 
Partnering News 
* Lilly, Stipple Bio in $5.9-Bn Oncology Precision Medicines Pact
* Pfizer, Starna Therapeutics in $2.6-Bn In Vivo CAR-T Pact  
* AbbVie, Disco Pharma in $2.5-Bn Pact for Bispecifics for Cancer 
* Seawolf Therapeutics Raises $100 M; Enters $1.2-Bn Pact with Sanofi
* Biogen, TrimTech Therapeutics in $411-M Small-Molecule Protein Degrader Pact 
* Vertex, Genomics Ltd Extend Drug-Discovery Pact with $220-M Deal
Pipeline & Product Updates 
* Merck & Co. Discontinues Late-Stage Development of Blood Cancer Drug 
ESG News 
* Novo Commits $200 M to World Diabetes Foundation Over 10 Years
* BeOne Medicines, CLL Society in Pact for Leukemia & Lymphoma Education
* Gilead Expands Access to Ebola Bundibugyo Virus Disease Treatments
* FDA Launches Global Reliance Disclosure Program


Shionogi Completes $2-Bn Acquisition of Intra Bio  
Shionogi has completed its acquisition of IntraBio, an Austin, Texas-based bio/pharmaceutical company developing and commercializing therapies for rare neurodegenerative diseases and genetic neurological diseases, for $2 billion.  

IntraBio’s lead commercial product is Aqneursa (levacetylleucine) for treating certain rare neurodegenerative diseases. It was approved by the US Food and Drug Administration (FDA) in September 2024 for neurological manifestations of Niemann-Pick disease Type C, a rare, inherited lysosomal storage disorder, in adults and pediatric patients and by the European Medicines Agency (EMA) in January 2026. It also was approved by FDA for the treatment of ataxia, a neurological condition characterized by the loss of full control of body movements, balance, and coordination, in adults and pediatric patients diagnosed with ataxia-telangiectasia (A-T), a rare, progressive, autosomal recessive genetic disorder that damages the nervous system, immune system, and other body organs. It is currently under review by EMA for adult and pediatric patients diagnosed with A-T. 

The acquisition strengthens Shionogi’s position in rare diseases. In April (April 2026), the company acquired the global rights to Radicava/Radicut (edaravone), a treatment for amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease, commonly known as Lou Gehrig’s disease, from Tanabe Pharma for $2.5 billion.   

Under the agreement, Shionogi paid a lump sum of $2 billion to acquire all outstanding shares of IntraBio, including global intellectual property and commercialization rights for Aqneursa. 

Source: Shionogi 


Lilly To Acquire Calytrix Bio for $1.5 Bn 
Eli Lilly and Company has agreed to acquire Calytrix Bio, a Wellesley, Massachusetts-based pre-clinical-stage bio/pharmaceutical company focused on rare blood cancers (myeloproliferative neoplasms [MPNs]), for $1.5 billion. 

Calytrix’s lead asset is preclinical biparatopic antibody for treating mutant calreticulin -driven essential thrombocythemia, a bone marrow condition that can cause blood clots, and myelofibrosis, a bone marrow-based blood cancer, designed provide disease-modifying therapy to support early intervention and long-term treatment. 

Under the agreement, Lilly will acquire Calytrix, and Calytrix shareholders could receive up to $1.5 billion in cash, inclusive of an upfront payment and subsequent payments upon the achievement of certain clinical and regulatory milestones. 

Source: Calytrix Bio 


Partnering News 

Lilly, Stipple Bio in $5.9-Bn Oncology Precision Medicines Pact 
Eli Lilly and Company and Stipple Bio, a Cambridge, Massachusetts-based preclinical bio/pharmaceutical company focused on targeted cancer therapies, have entered an agreement to discover tumor-specific cell surface epitope binders, in a deal worth up to $5.9 billion, inclusive of an upfront payment, milestone payments, and an equity investment from Lilly into Stipple. 

Stipple Bio’s proprietary platform, Pointillist Platform, identifies tumor-specific cell surface epitope binders to enable the development of high therapeutic index oncology therapies that selectively target tumor cells, with the potential to increase efficacy and reduce on-target, off-tumor toxicity. Under the agreement, Stipple will discover the epitope binders, and Lilly will combine them with its proprietary oncology technologies to advance high therapeutic index compounds across multiple modalities. 

Under the agreement, Stipple Bio will receive an upfront payment and an equity investment from Lilly. Lilly receives exclusive worldwide rights to develop and commercialize products arising from the collaboration. Stipple Bio will be eligible to receive aggregate payments of up to $5.9 billion dollars upon achievement of research, product development and commercialization milestones, as well as tiered royalties on product sales should Lilly successfully commercialize therapies from the collaboration. 

Source: Stipple Bio 


Pfizer, Starna Therapeutics in $2.6-Bn In Vivo CAR-T Pact  
Pfizer has entered into an exclusive licensing agreement with Starna Therapeutics, a Suzhou, China-based bio/pharmaceutical company developing RNA medicines to enable in vivo therapeutics in autoimmune disorders, for three in vivo chimeric antigen receptor T-cell (CAR-T) programs, in a deal worth up to $2.6 billion ($330 million upfront and $2.3 billion in milestone payments).  

Pfizer will obtain exclusive rights outside Greater China to develop, manufacture, and commercialize three pre-investigational new drug (IND) in vivo CAR-T programs that are focused on treating autoimmune diseases. Pfizer also receives rights to use Starna’s in vivo CAR-T technology in inflammation and immunology, and in oncology, as well as options to exclusively license compounds created under a separate research collaboration and an option to expand the territory to include exclusive rights to develop and commercialize each exclusively licensed compound and product in Greater China. 

Under the agreement, Starna will receive an upfront payment of $330 million and is eligible to receive up to $2.3 billion in milestone payments associated with certain development and commercial milestones, plus royalties on net sales of approved products. Pfizer will lead clinical development outside Greater China and plans to manufacture the finished drug product for the initial clinical trials using its facilities in the US. Pfizer will have sole and exclusive control over commercialization outside of Greater China for all products. Pfizer holds options to expand its territory to include Greater China. 

Source: Pfizer 


AbbVie, Disco Pharma in $2.5-Bn Pact for Bispecifics for Cancer 
AbbVie has formed a strategic collaboration and option- to-license agreement with Disco Pharmaceuticals, a Cologne, Germany-based preclinical-stage bio/pharmaceutical company, to discover and develop bispecific therapeutics for solid tumors, in a deal worth up to $2.5 billion ($40 million upfront and out to $2.5 billion in option, development, and other milestone payments). 

Disco Pharmaceuticals has a proprietary platform for designing AND-gated bispecific antibodies, T-cell engagers, and antibody-drug conjugates using its surfaceome mapping platform. The platform maps cancer-specific cell-surface presentation and expression patterns for identifying target pairs that enable selective tumor recognition. This approach enables the design of bispecific antibodies that bind with high avidity only when both target antigens are simultaneously engaged on the same tumor cell, a mechanism known as AND-gating. Through simultaneous engagement of both targets, AND-gated therapeutics have the potential to broaden the addressable target space and reduce on-target off-tumor toxicity, a key limitation of solid tumor therapies, according to information from Disco Pharmaceuticals. The company’s lead programs are progressing toward the clinic for small cell lung cancer and colorectal cancer. 

Under the agreement, DISCO will receive $40 million in upfront payments and is eligible for up to $2.5 billion in option, development, and other milestone payments, plus tiered royalties on worldwide net sales. 

Source: Disco Pharmaceuticals 


Seawolf Therapeutics Raises $100 M; Enters $1.2-Bn Pact with Sanofi 
Seawolf Therapeutics, a San Diego, California-based preclinical bio/pharmaceutical company, has debuted as a company by raising $100 million for advancing its drug portfolio via its proprietary lipid nanoparticle (LNP) DNA delivery platform and has formed a multi-target research collaboration and exclusive license agreement with Sanofi worth up to $1.2 billion.  

Seawolf’s LNP-based DNA delivery platform, Trident (Targeted RNA-Induced DNA Expression via Nuclear Translocation) enables the long-term, stable expression of therapeutic proteins in a non-immunogenic and redosable format. The company says the platform matches the potency, redosability, safety and scalability of RNA-based LNP therapies but overcomes their short-lived expression by delivering DNA-based payloads. To do so, the Trident system consists of a proprietary LNP carrying an immune quiet DNA that encodes a therapeutic transgene and an auxiliary factor that facilitates nuclear access. 

Investors in its $100-million Series A financing round included Versant, MPM BioImpact, and Novartis Venture Fund and participation from Eli Lilly and Company and CRISPR Therapeutics, among others.  

Seawolf also announced a multi-target research collaboration and exclusive license agreement with Sanofi to develop undisclosed therapies for bleeding disorders and additional unnamed indications for up to $1.2 billion in research, development & commercial milestones, as well as tiered royalties on sales of any products resulting from the collaboration. 

Source: Seawolf Therapeutics 


Biogen, Trimtech Therapeutics in $411-M Small-Molecule Protein Degrader Pact 
Biogen and Trimtech Therapeutics, a Cambridge, England-based bio/pharmaceutical company developing small-molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, have entered a strategic research collaboration, option, and license agreement for protein degraders, in a deal worth up to $411 million ($32 million upfront and $379 million in milestone payments). 

Under the agreement, Biogen and Trimtech will work collaboratively to discover and develop small-molecule protein degraders for the treatment of neurodegenerative diseases. Upon Biogen’s exercise of the option, the company will be granted a global exclusive license to the degraders developed and will be responsible for further development and commercialization activities. Under the agreement, Trimtech is eligible to receive up to $32 million in upfront and research milestone payments, with total potential payments of up to $411 million, plus royalties. 

Source: Trimtech Therapeutics 


Vertex, Genomics Ltd. Extend Drug-Discovery Pact with $220-M Deal 
Vertex Pharmaceuticals and Genomics Ltd, a drug-discovery and development company using large-scale genetic information, have announced a four-year extension of their drug-target discovery and validation collaboration, in a deal worth up to $220 million. The extension builds on an eight-year collaboration that originally commenced in 2018. 

The collaboration focuses on using human genetics for the discovery and validation of drug targets and biomarker selection for precision medicines and to advance understanding of the clinical impact of human genetic variation in diseases. 

The total potential contract value exceeds $220 million, for the successful achievement of certain research, development, regulatory and commercial milestones, and tiered royalties on future net sales for any products that may result from this collaboration agreement. 

Source: Genomics Ltd. 


Pipeline & Product Updates 

Merck & Co. Discontinues Late-Stage Development of Blood Cancer Drug  
Merck & Co. has announced the discontinuation of the clinical development program evaluating nemtabrutinib (MK-1026), an investigational, oral, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor. Nemtabrutinib was being evaluated in several Phase III clinical trials, including for chronic lymphocytic leukemia, small lymphocytic leukemia, and other hematologic malignancies. Merck acquired the drug through its $2.7-billion acquisition of ArQule in January 2020.  

Source: Merck & Co. 


ESG News 

Global Health/Patient Access 

Novo Commits $200 M to World Diabetes Foundation Over 10 Years 
Novo has announced a $200-million commitment to the World Diabetes Foundation (WDF) for 2027–2036. The funding will support WDF’s work to strengthen diabetes prevention and care in low- and middle-income countries. 

Source: Novo 


BeOne Medicines, CLL Society in Pact for Leukemia & Lymphoma Education 
BeOne Medicines, a Basel, Switzerland-headquartered bio/pharmaceutical company focused on oncology, and the CLL Society, an organization supporting chronic lymphocytic leukemia (CLL) patients, families, care partners, and medical professionals, have announced an expanded, multi-year partnership focused on strengthening education, engagement, and access to resources for the CLL/ small lymphocytic lymphoma (SLL) community. 

Through this new three-year partnership, BeOne is expanding its support for the CLL Society to $3 million to advance several initiatives to support the CLL/SLL community by expanding education, digital resources, and engagement programs designed to help patients, care partners, and healthcare providers navigate the treatment landscape. 

Source: BeOne Medicines 


Gilead Expands Access to Ebola Bundibugyo Virus Disease Treatments 
Gilead Sciences has signed royalty-free voluntary licensing agreements with three generic-drug  manufacturers to support potential future access to its investigational antiviral, obeldesivir, for  post-exposure prophylaxis (PEP) for Ebola Bundibugyo virus disease (BVD).  

The agreements cover 127 primarily low- and lower-middle-income countries, consistent with the geographic scope of Gilead’s existing voluntary licensing agreements for remdesivir, its antiviral drug for treating COVID-19, and include all African countries that have reported cases during the current Ebola BVD outbreak. The agreements are intended to support manufacturing readiness, technology transfer and supply planning while the ongoing Ebola Post-Exposure Prophylaxis Phase III field trial evaluates obeldesivir as PEP for Ebola BVD. 

Source: Gilead Sciences 


FDA Launches Global Reliance Disclosure Program  
The US Food and Drug Administration (FDA) has launched the Global Reliance Disclosure Program (GRDP), an initiative that enables the FDA to more efficiently share minimally redacted approval packages, including FDA’s detailed scientific and regulatory assessments, directly with companies who can then share them with regulatory authorities outside of the United States. 

The GRDP launched on October 30, 2026, with a President’s Emergency Plan for AIDS Relief (PEPFAR) tentative approval for lenacapavir, a drug indicated for both HIV prevention and treatment. FDA says the GRDP addresses a challenge in global health: the gap between regulatory approval in high-capacity countries and patient access in lower-resource settings. “When a drug is approved by the FDA, patients in many parts of the world may wait months or years longer for their own national health authority to complete an independent review due to limited regulatory capacity and resources,” said FDA in a November 17, 2026, statement in announcing the program. Beyond individual product approvals, FDA says the GRDP further supports global health security by facilitating harmonized regulatory decisions. 

FDA says it intends to expand the GRDP in January 2027 to all novel drug and biologics (new molecular entity new drug applications and 351(a) biologics license applications) to broaden the program’s reach and impact. In addition, FDA says it intends to launch a pathway in early 2027 to expedite an applicant’s ability to request their minimally redacted action packages for approved and licensed drugs and biologics,.   

Source: US Food and Drug Administration